BRCA and Pancreatic Cancer: Selection of Chemotherapy

  • Richard Kim H. Lee Moffitt Cancer Center. Tampa, FL, USA
  • Jenifer Byer University of South Florida. Tampa, FL, USA
  • Muhammad Wasif Saif Columbia University College of Physicians and Surgeons and New York Presbyterian Hospital. New York, NY, USA
Keywords: Drug Therapy, Genes, BRCA1, BRCA2, Mutation, Pancreatic Neoplasms


Germline mutations in BRCA genes are associated with increased risk of pancreatic cancer. There are pre clinical data which suggests that DNA cross linking agents should be used in pancreatic cancer patients with BRCA mutations. This review is an update from the 2012 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium regarding recent developments in the treatment of pancreatic cancer with BRCA mutation. Only one study (Abstracts #217) was presented and it is described here.


Download data is not yet available.


Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.

Narod SA, Foulkes WD. Brca1 and brca2: 1994 and beyond. Nat Rev Cancer 2004;4:665-76.

Cancer risks in brca2 mutation carriers. The breast cancer linkage consortium. J Natl Cancer Inst 1999;91:1310-6.

Murphy KM, Brune KA, Griffin C, Sollenberger JE, Petersen GM, Bansal R, et al. Evaluation of candidate genes map2k4, madh4, acvr1b, and brca2 in familial pancreatic cancer: Deleterious brca2 mutations in 17%. Cancer Res 2002;62:3789-93.

Stadler ZK, Salo-Mullen E, Patil SM, Pietanza MC, Vijai J, Saloustros E, et al. Prevalence of brca1 and brca2 mutations in ashkenazi jewish families with breast and pancreatic cancer. Cancer 2012;118:493-9.

Tran B MS, Zogopoulos G, Borgida A, Holter S, Gallinger S et al. Platinum-based chemotherapy (pt-chemo) in pancreatic adenocarcinoma (pc) associated with brca mutations: A translational case series. J Clin Oncol 2012;30:Abstract 217.

McCabe N, Lord CJ, Tutt AN, Martin NM, Smith GC, Ashworth A. Brca2-deficient capan-1 cells are extremely sensitive to the inhibition of poly (adp-ribose) polymerase: An issue of potency. Cancer Biol Ther 2005;4:934-6.

Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, et al. Pathologic complete response rates in young women with brca1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 2010;28:375-9.

Yang D, Khan S, Sun Y, Hess K, Shmulevich I, Sood AK, et al. Association of brca1 and brca2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 2011;306:1557-65.

van der Heijden MS, Brody JR, Dezentje DA, Gallmeier E, Cunningham SC, Swartz MJ, et al. In vivo therapeutic responses contingent on fanconi anemia/brca2 status of the tumor. Clin Cancer Res 2005;11:7508-15.

Chalasani P, Kurtin S, Dragovich T. Response to a third-line mitomycin c (mmc)-based chemotherapy in a patient with metastatic pancreatic adenocarcinoma carrying germline brca2 mutation. JOP 2008;9:305-8.

James E, Waldron-Lynch MG, Saif MW. Prolonged survival in a patient with brca2 associated metastatic pancreatic cancer after exposure to camptothecin: A case report and review of literature. Anti-Cancer Drugs 2009;20:634-8.

Farmer H, McCabe N, Lord CJ, Tutt ANJ, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in brca mutant cells as a therapeutic strategy. Nature 2005;434:917-21.

Fong PC, Boss DS, Yap TA, Tutt A, Wu PJ, Mergui-Roelvink M, et al. Inhibition of poly(adp-ribose) polymerase in tumors from brca mutation carriers. New England Journal of Medicine 2009;361:123-34.

Lowery MA, Kelsen DP, Stadler ZK, Yu KH, Janjigian YY, Ludwig E, et al. An emerging entity: Pancreatic adenocarcinoma associated with a known brca mutation: Clinical descriptors, treatment implications, and future directions. Oncologist 2011;16:1397-402.

H. Lee Moffitt Cancer Center. Tampa, FL, USA
How to Cite
KimR., ByerJ., & SaifM. (2012). BRCA and Pancreatic Cancer: Selection of Chemotherapy. JOP. Journal of the Pancreas, 13(2), 180-181.
Highlights from the “2012 ASCO Gastrointestinal Cancers Symposium”. San Francisco, CA, USA. January 19-21, 2012

Most read articles by the same author(s)